Trial Profile
A Phase 2 Study of Poziotinib in Patients With HER2-Positive Metastatic Breast Cancer (MBC) Who Have Received Prior HER2 Regimens for MBC
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Feb 2022
Price :
$35
*
At a glance
- Drugs Poziotinib (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Therapeutic Use
- Sponsors Spectrum Pharmaceuticals
- 29 Jul 2021 Status changed from active, no longer recruiting to completed.
- 04 Dec 2020 According to Spectrum media release, data from this trial would be presented at the upcoming San Antonio Breast Cancer Conference (SABCS) to be held December 8 - 11, 2020.
- 04 Dec 2018 Planned number of patients changed from 70 to 75.